Teva CFO Sees New Products Coming From Its NTEs & Israel’s R&D Hub
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s CFO says the world’s top generics maker is entering a growth period buoyed by emerging markets and an expanding pipeline that will include re-purposed drugs, allowing the company to offset revenue lost from patent expiries. He also believes innovative R&D in home market Israel will soon enjoy a renaissance.